COMMUNIQUÉS West-GlobeNewswire

Fulgent Genetics Reports Second Quarter 2018 Financial Results
06/08/2018
Second Quarter 2018 Results : Revenue totals $5.4 million, growing 16% year over year and 16% sequentially Billable tests delivered total 5,700, growing 47% year over year and 23% sequentially GAAP and non-GAAP gross [...]
Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/08/2018
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent [...]
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming registration-directed trial of [...]
Akcea Reports Financial Results and Highlights for Second Quarter 2018
06/08/2018
TEGSEDI™ (inotersen) Approved in European Union $382 million to fund the company through key milestones in 2019 Conference Call Webcast Monday, August 6, 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass., Aug. 06, 2018 ( [...]
Editas Medicine Announces Second Quarter 2018 Results and Update
06/08/2018
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101 Investigational New Drug [...]
Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
06/08/2018
Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care [...]
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
06/08/2018
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic [...]
Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results
06/08/2018
$48.8 million of proceeds from warrant exercises received through July 31 $36 million of additional senior notes issued and funded in June Initial SDS microarray verification and validation started Record reagent [...]
Gemphire Provides Update On Development of Gemcabene
06/08/2018
FDA requests the Company provide additional data regarding the partial clinical hold Company continues Phase 2 development of gemcabene for NAFLD/NASH Company amends loan agreement with SVB to provide additional [...]
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b [...]
Iovance Biotherapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
- Company to Host Conference Call at 4:30pm ET Today - SAN CARLOS, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies [...]
Achaogen Reports Second Quarter 2018 Financial Results and Provides Corporate Update
06/08/2018
-- ZEMDRI (plazomicin) , approved in the U.S. for the treatment of adults with complicated urinary tract infections -- -- Launch of ZEMDRI underway; reached more than three quarters of high priority accounts in first [...]
Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.
06/08/2018
LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, [...]
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
06/08/2018
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 10,454,546 shares of its common stock, [...]
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
06/08/2018
Reinforces both Allergan’s and Editas’ continued commitment to developing innovative treatments for unmet needs in eye care EDIT-101 is Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of [...]
Dynavax Reports Second Quarter 2018 Financial Results
06/08/2018
HEPLISAV-B® Launch Progressing as Planned with Key Customer Successes Three abstracts accepted for presentation at European Society for Medical Oncology (ESMO) 2018 Annual Meeting Conference Call to be held at 4:30pm ET [...]
Devonian Health Group provides an update on its previously announced private placement
06/08/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. QUEBEC CITY, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Devonian Health Group Inc. ( “Devonian” or the “Corporation” ) (TSX VENTURE:GSD), a [...]
Groupe Santé Devonian fournit une mise à jour sur son placement privé préalablement annoncé
06/08/2018
NE PAS DISTRIBUER AUX AGENCES DE PRESSE AMÉRICAINES NI DIFFUSER AUX ÉTATS-UNIS QUÉBEC, 06 août 2018 (GLOBE NEWSWIRE) -- Groupe Santé Devonian Inc. ( « Devonian » ou la « Société » ) (TSX CROISSANCE:GSD), une société [...]
ContraVir Pharmaceuticals Provides an Update to Corporate Objectives
06/08/2018
EDISON, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of [...]

Pages